What to do for a patient with dizziness and bradycardia on lisinopril for controlled Hypertension (HTN)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Dizziness and Bradycardia in a Patient on Lisinopril for Hypertension

Immediate Assessment and Action

Hold the lisinopril immediately and evaluate for symptomatic bradycardia requiring urgent intervention. 1

The first priority is determining whether this bradycardia is causing hemodynamic compromise. Check for:

  • Signs of hypoperfusion: altered mental status, chest discomfort, acute heart failure symptoms, oliguria, cool extremities 1, 2
  • Blood pressure measurement: systolic BP <100 mmHg with symptoms indicates need for immediate intervention 3, 2
  • 12-lead ECG: rule out high-degree AV block (second or third-degree), which would require different management 1, 4

Understanding the Clinical Context

While lisinopril alone rarely causes bradycardia directly 5, 6, several mechanisms may be contributing:

  • Medication interactions: Lisinopril can potentiate bradycardia when combined with other rate-lowering agents, though the patient is only on lisinopril 5 mg 7
  • Hypertension with left ventricular hypertrophy (LVH): The association of LVH with bradyarrhythmias, including sick sinus syndrome, has been observed in hypertensive patients 1
  • Sleep-disordered breathing: Both sinus node dysfunction and AV conduction disturbances may occur in hypertensive patients with sleep apnea, where electrophysiologic properties are normal while awake 1

Acute Management Protocol

If Hemodynamically Unstable (Symptomatic Bradycardia)

Administer atropine 0.5 mg IV every 3-5 minutes (maximum 3 mg total) as first-line therapy while arranging for definitive management. 1, 3

  • Monitor continuously for response: target heart rate >50-60 bpm with resolution of symptoms 3
  • If atropine fails, consider epinephrine (2-10 µg/min) or dopamine (2-10 µg/kg/min) 1
  • Transcutaneous pacing may be considered when full-dose atropine fails, though it may not be more effective than second-line drug therapy 1

If Hemodynamically Stable (Asymptomatic Bradycardia)

Continue holding lisinopril and observe closely with serial vital signs every 4-6 hours initially. 4

  • Bradycardia <60 bpm without symptoms generally requires no immediate treatment 4
  • However, if heart rate falls below 40 bpm, even in asymptomatic patients, closer monitoring is warranted 4

Diagnostic Workup

Obtain the following to identify underlying causes:

  • ECG with rhythm strip: Document bradycardia type (sinus bradycardia vs. AV block) and assess for conduction abnormalities 1, 4
  • Electrolytes: Check potassium (lisinopril can cause hyperkalemia in 2.2% of hypertensive patients), sodium, and renal function 5
  • Thyroid function (TSH): Rule out hypothyroidism as alternative cause 2
  • Sleep study consideration: Screen for obstructive sleep apnea, particularly if patient has risk factors (obesity, snoring, daytime somnolence), as this is a reversible cause of bradycardia in hypertensive patients 1

Long-Term Management Strategy

Restarting Antihypertensive Therapy

Once bradycardia resolves and blood pressure remains controlled, lisinopril can typically be restarted at the same dose (5 mg daily). 5, 6

  • Lisinopril 5 mg is a low dose with good tolerability profile 5, 6
  • Monitor heart rate and blood pressure at 1-2 week follow-up 3
  • Target blood pressure <130/80 mmHg per current guidelines 3

If Bradycardia Persists or Recurs

Consider alternative antihypertensive agents that do not affect heart rate:

  • Amlodipine or other dihydropyridine calcium channel blockers: Do not cause bradycardia and combine well with ACE inhibitors 1
  • Continue ACE inhibitor therapy: ACE inhibitors do not cause bradycardia and provide mortality benefit 2
  • Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil): Risk of bradycardia and AV block, particularly when combined with beta-blockers 1

If Underlying Conduction Disease is Identified

Treat the primary cause:

  • Obstructive sleep apnea: Continuous positive airway pressure (CPAP) can reverse bradyarrhythmias and reduce blood pressure 1
  • Symptomatic sick sinus syndrome or high-degree AV block: May require permanent pacemaker implantation, particularly in hypertensive patients with LVH 1

Critical Pitfalls to Avoid

  • Do not assume dizziness is solely from hypotension: Symptomatic bradycardia can cause cerebral hypoperfusion with dizziness even with normal blood pressure 1
  • Do not restart lisinopril if bradycardia persists: Wait for heart rate to consistently exceed 55-60 bpm 2
  • Do not add beta-blockers or non-dihydropyridine calcium channel blockers: These will worsen bradycardia 1
  • Do not ignore sleep apnea screening: This is a common, reversible cause of bradycardia in hypertensive patients that also improves blood pressure control 1

Monitoring Parameters

Schedule follow-up within 1-2 weeks to assess:

  • Heart rate and blood pressure response 3
  • Resolution of dizziness symptoms 1
  • Blood pressure control (target <130/80 mmHg) 3
  • Development of any new symptoms suggesting worsening conduction disease 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Beta Blocker Intolerance and Withdrawal Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Metoprolol Treatment Protocol for Hypertension and Heart-Related Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Asymptomatic Bradycardia in Patients on Beta Blockers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The clinical pharmacology of lisinopril.

Journal of cardiovascular pharmacology, 1987

Research

Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.